pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,434 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1219Endpoints923BioPharma Dive354BioSpace340Fierce Biotech322onclive165raps111globenewswire health73
therapy area
allOncology8299Rare Disease1943Cardiology1880Immunology1591Hematology1354Pulmonology1296Vaccines
  • New U.S. hepatitis B vaccine policy targeting only at-risk newborns could raise infant infections and costs, studies warn
    A new U.S. recommendation limits the birth‑dose hepatitis B vaccine to infants who are judged to be at risk of neonatal infection, rather than offering it universally to all newborns. One study co…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Oruka’s experimental psoriasis drug achieves near-complete skin clearance in Phase 2 trial
    Oruka Therapeutics reported that its experimental IL-23 inhibitor ORKA-001 cleared the skin of 40 of 63 patients (about 63%) in a Phase 2 study, achieving a PASI 100 response at 16 weeks. A further…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
← prev
page 135 of 138
next →
fda recalls71
fda medwatch63
fda press38
1279
Psychiatry & CNS899
Ophthalmology521
Pain503
Endocrinology & Metabolism497
Infectious Disease459
  • Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion to develop improved JAK inhibitor
    Eli Lilly announced Monday it will purchase Ajax Therapeutics, a biotech based in New York and Cambridge, Massachusetts, in a deal valued at up to $2.3 billion. The transaction includes cash up fr…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Eli Lilly to pay up to $2.3B for Ajax's JAK inhibitor in cancer deal
    Eli Lilly announced a new agreement with Ajax Therapeutics to acquire rights to a JAK inhibitor called Kyle LaHucik for cancer treatment. The transaction could be worth up to $2.3 billion, reflect…
    Endpoints · 4mo agoDealPositive↗ source
  • Compass Therapeutics reports secondary endpoint data from pivotal biliary tract cancer trial, shares stock drop
    Compass Therapeutics announced new secondary‑endpoint results from its pivotal bispecific antibody trial in second‑line biliary tract cancer, a year after reporting a Phase 2/3 success. The additi…
    Endpoints · 4mo agoNegative readoutNegative↗ source
  • Oruka's yearly injectable shows 63% complete clearance in mid-stage psoriasis trial
    Oruka Therapeutics reported results from a Phase 2 trial of its long-acting injectable, ORKA-001, in patients with plaque psoriasis. In the study, 63% of participants achieved complete skin cleara…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Supreme Court split on blocking thousands of Roundup cancer lawsuits
    The Supreme Court heard arguments on Monday about whether to block thousands of lawsuits claiming the weedkiller Roundup caused cancer, and the justices appeared divided. The dispute follows a wav…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Erasca reports early trial shows tumor shrinkage in 40% of pancreatic and 62% of lung cancer patients
    Erasca announced that its experimental RAS-targeting oral drug, ERAS-0015, produced tumor reductions in a portion of patients with advanced pancreatic cancer and advanced non-small cell lung cancer…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Erasca releases early-stage RAS drug data amid legal dispute with Revolution Medicines
    Erasca has released early-stage data on its RAS-targeting compound, doing so after receiving a legal threat from rival Revolution Medicines. Revolution recently announced a new drug that revived h…
    Endpoints · 4mo agoNeutral↗ source
  • Thermo Fisher to divest microbiology unit to Astorg for $1.075 billion; Ligand announces purchase of XOMA
    Thermo Fisher Scientific announced it will sell its microbiology business, part of its specialty diagnostics segment, to European private‑equity firm Astorg. The transaction is valued at $1.075 bi…
    Endpoints · 4mo agoDealNeutral↗ source
  • Oruka Therapeutics reports Phase 2 psoriasis results with 63% of patients showing plaque improvement
    Oruka Therapeutics announced results from its Phase 2 trial in moderate to severe plaque psoriasis. The study enrolled 63 patients and 40 of them, about 63.5%, achieved the predefined level of ski…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • AI-driven biotech Fathom Therapeutics secures $47 million Series A funding and rebrands from Atommap
    Fathom Therapeutics, the company formerly known as Atommap, announced that it has closed a $47 million Series A financing round. The capital raise will support the firm’s effort to combine artifici…
    Endpoints · 4mo agoDealPositive↗ source
  • FDA greenlights Motif Neurotech's feasibility trial of brain-implant hat for treatment-resistant depression
    The U.S. Food and Drug Administration has approved Motif Neurotech's request to begin an initial feasibility trial of its brain‑implant device aimed at patients with treatment‑resistant depression.…
    STAT · 4mo agoCRLPositive↗ source
  • Trump administration cautions against federal funding for fentanyl test strips and other harm-reduction tools
    The federal agency that oversees addiction and mental health policy sent an open letter to its grant recipients warning them not to spend federal money on harm‑reduction supplies such as sterile sy…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Veradermics reports positive Phase 2/3 results for oral Rogaine in men with pattern hair loss
    Veradermics, a biotech that recently went public, announced that its oral formulation of Rogaine met the primary endpoints in a late-stage Phase 2/3 trial. The study enrolled men with mild-to-mode…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Veradermics reports positive late-stage results for oral hair-loss pill VDPHL01
    Veradermics announced that its experimental oral medication VDPHL01 met its primary goals in a Phase 3 trial for male pattern hair loss. Over six months, participants taking the drug once or twice…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Revolution Medicines threatens lawsuit against Erasca over RAS drug patent and efficacy claims
    Earlier this month a newly announced cancer therapy generated strong interest from patients and investors. The drug, which targets the RAS pathway, was highlighted for its potential impact on oncol…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • Insider explains the true purpose behind prior authorizations in U.S. health insurance
    The STAT+ newsletter article by Bob Herman reports on an interview with Archelle Georgiou, who previously worked at the nation’s largest health insurer and was involved in efforts to curb prior aut…
    STAT · 4mo agoNeutral↗ source
  • STAT+: Astellas retries XLMTM gene therapy after deaths
    Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
    STAT · 4mo agoRegulatoryNeutral↗ source
  • GLP-1 drugs and eating disorder risk examined as Covid impact wanes in 2026
    The Morning Rounds newsletter explores the potential link between GLP-1 medications and the development of eating disorders, emphasizing that the risk remains uncertain and warrants further study.…
    STAT · 4mo agoNeutral↗ source
  • CDC-funded hepatitis B vaccine trial in Guinea-Bissau paused amid ethical concerns
    The U.S. Centers for Disease Control and Prevention awarded a $1.6 million grant to a Danish research group to compare hepatitis B vaccination at birth versus at six weeks in infants from Guinea‑Bi…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Utah doctors urge state to suspend Doctronic AI prescription-refill program
    Utah medical licensing board members have asked the state to halt a temporary program that lets startup Doctronic use artificial intelligence to refill prescriptions. The board says the AI-driven…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • NIH-funded studies often omit sex-specific results, study finds
    A new analysis of NIH-funded papers reveals that less than half report outcomes separately for men and women. Researchers examined 574 articles published between 2017 and 2024; while 61% included…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Experts say Covid risk has faded, but boosters still advised for vulnerable groups
    Health journalist Helen Branswell reflects on how Covid-19, once the dominant global threat, has receded in public consciousness. Six years after the 2020 lockdowns, mask-wearing and social distanc…
    STAT · 4mo agoNeutral↗ source
  • Mental health clinicians face contracts that charge patients for staying with them
    Sarah Cady, a psychiatric nurse practitioner near New York City, discovered a clause in an employment contract that would require her to pay $7,500 for each patient who chose to continue treatment…
    STAT · 4mo agoNegative↗ source